By Mohamed Diagne  By the year 2000, pharmaceutical companies had convinced medical professionals across the United States that opioid analgesics  – a highly potent painkiller that successfully marketed  itself as a therapeutic drug in the  late 1990s – would not deleteriously affect the mental stability of patients, nor make them overly dependent on the relief it provided (Meier). After years of tense debate on whether … Continue reading The Black Opioid Epidemic: The irreparable impact of a single pharmaceutical company on the black community